Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.5 PLN | -2.33% | +7.71% | -5.22% |
May. 17 | Transcript : Ryvu Therapeutics S.A. - Special Call | |
Mar. 13 | Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.22% | 329M | - | ||
+9.95% | 115B | B+ | ||
+11.90% | 106B | B+ | ||
-2.59% | 21.96B | B | ||
-12.20% | 21.87B | B+ | ||
-5.29% | 19.21B | A- | ||
-4.11% | 18.08B | B | ||
-38.57% | 17.71B | A- | ||
+7.21% | 14.32B | C+ | ||
+35.24% | 12.42B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RVU Stock
- Ratings Ryvu Therapeutics S.A.